Old gout drug tested as new hope for advanced liver cancer
NCT ID NCT04264260
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase 2 trial tested colchicine, a drug usually used for gout, in 42 people with advanced liver cancer that could not be treated with curative intent. Participants took colchicine tablets daily in cycles of 4 days on, 3 days off. The study measured how long patients survived and tracked side effects. Results were compared to similar patients from past records, not a placebo group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Colchicine tablets
What this could lead to
If it works, this could offer a new palliative option to help people with advanced liver cancer live longer and manage symptoms.
What could go wrong
This is a small, early-phase trial with only 42 participants and no randomized control group. Colchicine may cause side effects and might not improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA STAGE IIIB are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kaohsiung Medical University Hospital
Kaohsiung City, 807, Taiwan